Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 1984 Mar-Apr;9(2):177-83.
doi: 10.2165/00003088-198409020-00005.

The influence of obesity on the pharmacokinetics of oral alprazolam and triazolam

D R Abernethy, D J Greenblatt, M Divoll, R B Smith, R I Shader

The influence of obesity on the pharmacokinetics of oral alprazolam and triazolam

D R Abernethy et al. Clin Pharmacokinet. 1984 Mar-Apr.

Abstract

12 obese patients, pair-matched with 12 normal subjects, received a single 1 mg oral dose of alprazolam. Nine similar subject pairs received a single 0.5 mg oral dose of triazolam. Oral volume of distribution (Vd) was much greater in obese than control subjects for alprazolam (mean 114 vs 73L, p less than 0.001), but there was no difference between the 2 groups for triazolam (117 vs 116L). Apparent oral clearance (not corrected for body weight) of alprazolam was lower, although not significantly so, in obesity (66 vs 88 ml/min), but for triazolam it was much lower in the obese (340 vs 531 ml/min, p less than 0.005). Elimination half-life, which is dependent on both Vd and clearance, was prolonged in obesity for alprazolam (22 vs 11h, p less than 0.001) due to the increase in Vd, and also for triazolam (4.1 vs 2.6 h, p less than 0.025) because of the decreased clearance. Plasma protein binding was unchanged in obese compared with control subjects for both alprazolam and triazolam. During long term administration alprazolam should therefore take longer to reach steady-state concentrations in obese patients but the final levels achieved should be no different than for patients of normal bodyweight, provided dosage is adjusted for ideal rather than total bodyweight. In contrast, triazolam has impaired clearance in obesity. However, if given once-daily it still would not accumulate with long term dosing due to its short half-life relative to the interval between doses.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. J Pharm Sci. 1982 Aug;71(8):942-4 - PubMed
    1. J Chronic Dis. 1970 Aug;23(2):93-103 - PubMed
    1. Clin Pharmacol Ther. 1981 Jan;29(1):81-93 - PubMed
    1. J Lab Clin Med. 1983 Jun;101(6):873-80 - PubMed
    1. Clin Pharmacol Ther. 1982 Jun;31(6):783-90 - PubMed

Publication types

LinkOut - more resources